Enoxaparine Becat 8000 IU (80 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr. Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 8000 iu (80 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 8000 iu (80 mg)/0,8 ml - enoxaparin sodium 10000 iu/ml - enoxaparin

Enoxaparine Becat 10000 IU (100 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr. Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 10000 iu (100 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 10000 iu (100 mg)/1 ml - enoxaparin sodium 10000 iu/ml - enoxaparin

Enoxaparine Becat 12000 IU (120 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr. Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 12000 iu (120 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 12000 iu (120 mg)/0,8 ml - enoxaparin sodium 15000 iu/ml - enoxaparin

Enoxaparine Becat 15000 IU (150 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr. Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 15000 iu (150 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 15000 iu (150 mg)/1 ml - enoxaparin sodium 15000 iu/ml - enoxaparin

Enoxaparin Sandoz 2000 IU (20 mg) 0.2 mL Solution for Injection in Pre-filled Syringe Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 2000 iu (20 mg) 0.2 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

Enoxaparin Sandoz 4000 IU (40 mg) 0.4 mL Solution for Injection in Pre-filled Syringe Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 4000 iu (40 mg) 0.4 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

Enoxaparin Sandoz 6000 IU (60 mg) 0.6 mL Solution for Injection in Pre-filled Syringe Malasja - Ingliż - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 6000 iu (60 mg) 0.6 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

ARIXTRA- fondaparinux sodium injection, solution Stati Uniti - Ingliż - NLM (National Library of Medicine)

arixtra- fondaparinux sodium injection, solution

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - arixtra® is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): arixtra is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. arixtra is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. arixtra is contraindicated in the following conditions: available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with arixtra during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see

ENOXAPARIN INHIXA Iżrael - Ingliż - Ministry of Health

enoxaparin inhixa

k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml - enoxaparin - enoxaparin inhixa is indicated in adults for:• prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

ENOXAPARIN INHIXA FORTE Iżrael - Ingliż - Ministry of Health

enoxaparin inhixa forte

k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin inhixa forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).